Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients

详细信息    查看全文

• 作者：Taichiro Goto ; Yosuke Hirotsu ; Toshio Oyama ; Kenji Amemiya ; Masao Omata
• 关键词：Bone marrow ; Circulating tumor DNA ; Lung cancer ; Next ; generation sequencing ; Plasma
• 刊名：Medical Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：33
• 期：3
• 全文大小：486 KB
• 参考文献：1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef PubMed
  2.Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004. J Thorac Oncol. 2011;6:1229–35.CrossRef PubMed
  3.Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–40.CrossRef PubMed
  4.Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123:1991–2006.CrossRef PubMed
  5.Sugio K, Kase S, Sakada T, Yamazaki K, Yamaguchi M, Ondo K, et al. Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and b-catenin: risk assessment by immunohistochemistry. Surgery. 2002;131:226–31.CrossRef
  6.Yasumoto K, Osaki T, Watanabe Y, Kato H, Yoshimura T. Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg. 2003;76:194–201.CrossRef PubMed
  7.Saito T, Kobayashi M, Harada R, Uemura Y, Taguchi H. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro–gastrin-releasing peptide mRNA. Cancer. 2003;97:2504–11.CrossRef PubMed
  8.Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, et al. Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin Cancer Res. 2007;13:3840–7.CrossRef PubMed
  9.Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.PubMedCentral PubMed
  10.Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209.CrossRef PubMed
  11.Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.CrossRef
  12.Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.CrossRef
  13.Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3:121–9.PubMedCentral CrossRef PubMed
  14.Fidler IJ. The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.CrossRef PubMed
  15.Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011;29:4313–9.PubMedCentral CrossRef PubMed
  16.Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.PubMedCentral CrossRef PubMed
  17.Garcia-murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:1–12.CrossRef
  
• 作者单位：Taichiro Goto (1)
  Yosuke Hirotsu (2)
  Toshio Oyama (3)
  Kenji Amemiya (2)
  Masao Omata (2) (4)
  
  1. Department of General Thoracic Surgery, Yamanashi Prefectural Central Hospital, Yamanashi, Japan
  2. Genome Analysis Center, Yamanashi Prefectural Central Hospital, Yamanashi, 400-8506, Japan
  3. Department of Pathology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan
  4. The University of Tokyo, Tokyo, Japan
  
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

Liquid biopsies such as circulating tumor DNA in plasma and disseminated tumor cells in the bone marrow are currently available. However, it is unclear which types of samples are appropriate for detecting tumor DNA in these biopsies. Here, we collected primary tumors, pulmonary venous blood, peripheral blood, and rib bone marrow fluid from 10 lung cancer patients. Targeted deep sequencing was performed to identify mutations across 70 specimens. As a result, a total of 43 mutations were identified in the primary tumors. The mutation in the tumors was also identified in circulating tumor DNA in the pulmonary venous and peripheral blood in two patients. These patients showed poor prognosis, as compared to the other patients. However, no mutation was identified in the bone marrow in any of the patients. These results demonstrated that circulating tumor DNA in plasma is more sensitive and clinically useful as a biomarker as compared to DNA in bone marrow fluid.